Immunotherapies in Multiple Myeloma: A Practical Approach to Optimizing Care and Managing Treatment-Related Toxicities
Journal of the Advanced Practitioner in Oncology · 2026-11-09 · 17 (7)
DOI: 10.6004/jadpro.2026.17.7.32 ↗Abstract
Immunotherapies have heavily contributed to disease control in multiple myeloma and are often included in treatment regimens due to their strong efficacy and general tolerability. This broad class of drugs includes immunomodulatory drugs, monoclonal antibodies, cellular therapies with CAR T and NK cells, and bispecific antibodies. Strategies to mitigate toxicities lack standardization and vary across institutions. This article provides advanced practitioners with information regarding the most common immunotherapies and recommendations to manage common treatment toxicities based on consensus recommendations by myeloma experts and the International Myeloma Working Group.
EUVIMED